Also known as: Unnatural Products
Unnatural Products is a California biotech company developing synthetic macrocyclic peptides for challenging drug targets. The company uses an AI-enhanced discovery platform to design, synthesize, and screen macrocycles for unmet medical needs.
Novartis posted Q2 2026 earnings above expectations but a 50% drop in Entresto sales from U.S. generics hurt performance. The company highlighted new EU and Japan approvals for Rhapsido and Itvisma, and a manufacturing restructuring including a German plant closure and investment in radioligand production. A $1.8 billion peptide drug pact with Unnatural Products was also announced.
Novartis has announced three separate partnership deals worth over $5 billion combined with Antares Therapeutics, Orionis Biosciences, and Unnatural Products. The agreements target undruggable cancers, molecular glue drugs, and cardiovascular therapies respectively using each partner's proprietary platforms.
Novartis has entered a research and licensing agreement worth up to $1.8 billion with Unnatural Products to develop oral peptide medicines targeting cardiovascular disease using macrocyclic peptide technology.
Novartis has signed a research partnership and licensing agreement with Unnatural Products valued at up to $1.8 billion to develop macrocyclic peptide therapeutics targeting cardiovascular diseases using AI-driven drug discovery.
Unnatural Products entered a research collaboration and licensing agreement with Novartis worth up to $1.8 billion to develop orally-delivered macrocyclic peptide therapeutics for an undisclosed cardiovascular program.
